The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Novel strategies showing promise for high-risk multiple myeloma: combinations of T-cell engagers
Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, comments on novel strategies showing promise for high-risk multiple myeloma. He highlights the potential of combination therapy with T-cell engagers, such as teclistamab and daratumumab. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
What I think is the most important about high-risk is to be able to treat it with the most active treatments that we have. And what has happened here, I think, is that we start to see the importance of combination therapy with T-cell engagers. So the TEC-3 dataset shows superb activity when you combine teclistamab with daratumumab. And so where I think the future lies is identifying high risk at present with the presentation with the consensus genomic stratifier, find those patients, and then hopefully move T-cell engagers to the frontline setting...
What I think is the most important about high-risk is to be able to treat it with the most active treatments that we have. And what has happened here, I think, is that we start to see the importance of combination therapy with T-cell engagers. So the TEC-3 dataset shows superb activity when you combine teclistamab with daratumumab. And so where I think the future lies is identifying high risk at present with the presentation with the consensus genomic stratifier, find those patients, and then hopefully move T-cell engagers to the frontline setting. And there’s some really interesting data here. We present some work on linvoseltamab as a single agent in newly diagnosed patients, and people go into remissions, deep remissions. They tolerate it. And so for me, I think combining a T-cell engager with either daratumumab or even a triplet with an IMiD drug offers real potential for patients with high-risk disease to overcome the poor prognosis in that subgroup without giving them more side effects. And so I think these are very exciting times for everybody because the treatment paradigm is really changing where when you can get 100% of people to MRD negative complete responses, I think that’s a substantial step forward. All we need to do now is just generate the data on patients in the clinic who I think are going to benefit from these therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
